Navigation Links
Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
Date:9/30/2008

BOSTON, Sept. 30 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company intends to expand their current industry to include and capitalize on the $30 billion minimally invasive instrumentation market by implementing a business strategy. The Company's strategy is expected to substantially increase its revenue, and simultaneously increase its customer base.

Solos Endoscopy expects continuous growth in this market because physicians are developing new minimally invasive techniques, not only in the traditional area of general surgery, but also in other medical specialty areas. This shift in the Company's business strategy will allow many more procedures to be performed outside the operating room setting and this expansion creates an increased demand for high quality instrumentation in the medical product market.

"Our initiative for 2008 is to enhance the instrumentation that we have developed in the general surgery line, and to move our surgical instrument division into diverse specialties. We believe that we have a great future; our reputation in the medical industry is that we build excellent instruments and this, coupled with our new products, will significantly expand our revenue and customer base in the future," stated Robert Segersten, President of Solos Endoscopy, Inc.

For additional information on Solos Endoscopy, Inc. please visit http://www.solosendoscopy.com .

About Solos Endoscopy, Inc.

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: http://www.solosendoscopy.com .

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
2. New England Peptide Implements Quality Management System, Prepares for ISO 9001: 2008 Registration
3. Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell
4. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
5. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
6. Covance Decides to Pursue Its Original Preclinical Strategy in China
7. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
8. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
9. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
10. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
11. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 - And Other Rising ... of Those Competitor Biologics  - Biosimilar Drug ... Prospects ,  Who are the most important ... are their sales potentials? Discover, in our updated survey, ... opportunities and revenue forecasting. Visiongain,s ...
(Date:5/2/2016)... 2, 2016 Q BioMed Inc. ... partner Mannin Research Inc. will be attending the Association ... place from May 1-5, 2016 in Seattle ... with its vendors and research partners. The meeting provides ... and other collaborative opportunities for the MAN-01 program for ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design ... the bioLogic team explored how bacterial properties can be applied to fabric and formed ... bacteria, which move in response to humidity change. The team harvested Natto cells and ...
(Date:4/29/2016)... ... 2016 , ... During a two day program for start-up ... CereScan’s CEO, John Kelley, joined other Denver business leaders in providing business basics ... Denver area business community, shared his top fundamental learnings in building an effective, ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/14/2016)... 14, 2016 NXTD ) ("NXT-ID" or ... market, announces the airing of a new series of commercials ... of March 21 st .  The commercials will air on ... Squawk on the Street show. --> NXTD ) ... mobile commerce market, announces the airing of a new series ...
(Date:3/10/2016)... --  Unisys Corporation (NYSE: UIS ) today announced ... testing its biometric identity solution at the Otay Mesa border ... identify certain non-U.S. citizens leaving the country. ... determine the efficiency and accuracy of using biometric technologies in ... until May 2016. --> the United States ...
Breaking Biology News(10 mins):